<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Haur Yueh Lee, MRCP, M Med (Int Med), FAMS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">N Franklin Adkinson, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maja Mockenhaupt, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H574477680"><span class="h1">INTRODUCTION AND CLASSIFICATION</span><span class="headingEndMark"> — </span>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions characterized by extensive necrosis and detachment of the epidermis. Mucous membranes are affected in more than 90 percent of patients, usually at two or more distinct sites [<a href="#rid1">1</a>].</p><p>SJS and TEN exist as a continuum and are classified based on the percentage of skin body surface area (BSA) detached [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>&lt;10 percent of BSA detached – SJS</p><p class="bulletIndent1"><span class="glyph">●</span>10 to 30 percent of BSA detached – SJS/TEN overlap</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;30 percent of BSA detached – TEN</p><p></p><p>The term "epidermal necrolysis" has been used to refer collectively to SJS, SJS/TEN overlap, and TEN [<a href="#rid3">3</a>].</p><p>The pathogenesis, clinical manifestations, and diagnosis of SJS/TEN are discussed in this topic. Treatment, prognosis, and long-term complications are discussed separately. Other drug eruptions are reviewed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15761.html" rel="external">"Acute generalized exanthematous pustulosis (AGEP)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15760.html" rel="external">"Fixed drug eruption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">"Lichenoid drug eruption (drug-induced lichen planus)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">"Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors"</a>.)</p><p></p><p class="headingAnchor" id="H1845207170"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H39945580"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>SJS/TEN is a rare condition. The estimated incidence across the disease spectrum is five to six cases per million per year [<a href="#rid4">4-6</a>]. In the United States, the incidence of SJS, SJS/TEN, and TEN in the pediatric population was 5.3, 0.8, and 0.4 cases per million children per year, respectively [<a href="#rid7">7</a>].</p><p>In a multinational case-control study that included 379 cases, the median age was 50 years [<a href="#rid8">8</a>]. Similarly, in another French study of 2635 incident cases from four national databases, the median age was 52 years [<a href="#rid5">5</a>].</p><p>SJS/TEN is more common in females, with a female-to-male ratio of approximately 2:1 [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H1640994061"><span class="h2">Risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human immunodeficiency virus</strong> –<strong> </strong>Patients with human immunodeficiency virus (HIV) infection have an increased risk of SJS/TEN. In European cohort studies, the prevalence of HIV infection among patients with SJS/TEN was 7 to 9 percent; patients with HIV infection had a 12-fold increased risk of SJS/TEN [<a href="#rid9">9,10</a>]. In a retrospective study of 177 cases of SJS/TEN treated in dermatology departments/intensive care units in sub-Saharan Africa, the prevalence of HIV infection was 55 percent [<a href="#rid11">11</a>]. This heightened risk for SJS/TEN in patients with HIV infection is likely due to multiple factors, including the use of high-risk medications for the treatment of HIV (eg, <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a>) and opportunistic infections (eg, co-trimoxazole, tuberculosis medications) as well as the immune dysregulation associated with HIV [<a href="#rid12">12-14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Connective tissue disease</strong> – Patients with connective tissue disease have a twofold increased risk of SJS/TEN compared with patients without connective tissue disease [<a href="#rid8">8,15</a>]. However, because acute forms of cutaneous lupus erythematosus may mimic TEN (TEN-like lupus erythematosus), the risk may be overestimated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy</strong> – Patients with cancer have an increased risk of SJS/TEN. In a case-control study (EuroSCAR) of 379 cases and 1505 controls, a recent cancer diagnosis and radiation therapy were more common among cases of SJS/TEN, occurring in 10.6 and 4.2 percent versus 1.9 and 0.5 percent in controls, respectively [<a href="#rid8">8</a>]. In an analysis of a large cohort of over 100,000 patients with cancer identified from electronic health records between 2002 and 2015, the estimated annual incidence of confirmed and possible cases of SJS/TEN were 5.7 and 14.9 per 100,000 per year, respectively [<a href="#rid16">16</a>]. These rates are approximately 30 to 60 times higher than in the general population. In that cohort, the most common triggers were <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, and idiopathic causes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Older adults</strong> – The incidence of SJS/TEN is higher in older patients. In an analysis of four French databases, the estimated annual incidence of SJS/TEN among individuals ≥65 years was 13.7 cases per million compared with 4.1 cases per million among individuals &lt;20 years of age and 3.9 cases per million among those aged 20 to 64 years [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethnicity</strong> – A United Kingdom study utilizing the Clinical Practice Research Datalink from 1995 to 2013 found a twofold and threefold increased risk of SJS/TEN among Black and Asian people, respectively, compared with White people [<a href="#rid6">6</a>]. Similar findings were reported in a study from the United States using data from the Nationwide Inpatient Sample from 2009 to 2012 [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other factors</strong> – Increased drug doses and impaired renal function have been associated with an increased risk of allopurinol-induced SJS/TEN [<a href="#rid17">17-19</a>].</p><p></p><p class="headingAnchor" id="H3199253136"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>In a comprehensive survival analysis of a cohort of patients recruited from Austria, France, Germany, Israel, Italy, and the Netherlands (Registry of Severe Cutaneous Adverse Reactions [RegiSCAR]; n = 460), the overall mortality rate for SJS/TEN during the acute episode was 23 percent, varying from 12 to 49 percent across the SJS/TEN severity spectrum [<a href="#rid9">9</a>]. However, at one year, the overall mortality for SJS/TEN increased to 34 percent, likely due to severe comorbidities and older age.</p><p>Based on data from the 2009 to 2012 Nationwide Inpatient Sample, the mortality in the pediatric population was 0 percent for SJS, 4 percent for SJS/TEN, and 16 percent for TEN [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H2262712423"><span class="h1">ETIOLOGY</span></p><p class="headingAnchor" id="H3089871059"><span class="h2">Medications</span><span class="headingEndMark"> — </span>In most cases, SJS/TEN is a severe cutaneous reaction to medications.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-risk medications</strong> – Although the list of causative medications is long, several epidemiologic studies have demonstrated that the majority of such cases are due to a group of high-risk medications  (<a class="graphic graphic_table graphicRef91163" href="/z/d/graphic/91163.html" rel="external">table 1</a>) [<a href="#rid8">8,20-22</a>].</p><p></p><p class="bulletIndent1">Several novel anticancer therapies, such as immune checkpoint inhibitors (ICIs; eg, <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a>), have been associated with SJS/TEN [<a href="#rid23">23,24</a>]. Based on a meta-analysis of 20 randomized trials (11,597 patients), the use of ICIs was associated with a fourfold increased risk of SJS/TEN [<a href="#rid25">25</a>]. These reactions occurred at a median of 26 days since starting treatment, and the overall mortality was 37 percent [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">However, some ICI-related cases may represent SJS/TEN-like reactions that mimic SJS/TEN clinically and/or histologically [<a href="#rid27">27-29</a>]. Unlike true SJS/TEN, ICI-induced SJS/TEN-like reactions are believed to be severe immune-mediated bullous eruptions due to enhanced ICI cytotoxicity [<a href="#rid26">26,29,30</a>]. (See  <a class="medical medical_review" href="/z/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – The causative medication is typically started between one week to one month (occasionally up to two months) prior to the onset of symptoms. Drugs that are prescribed outside of this "at-risk" period are unlikely to be the cause of SJS/TEN.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protopathic bias</strong> – Caution must be exercised to avoid the so-called "protopathic bias," whereby medications that are used to treat the initial symptoms of SJS/TEN (eg, flu/cold medications, antibiotics) are erroneously assumed to be the culprits for the reaction.</p><p></p><p class="headingAnchor" id="H3398772340"><span class="h2">Other causes</span><span class="headingEndMark"> — </span>In at least 15 percent of cases, no clear drug causality can be found [<a href="#rid22">22</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – <em>Mycoplasma</em> infection has been identified in less than 30 percent of such idiopathic cases and should be considered when drug causality is unclear [<a href="#rid31">31</a>]. However, <em>Mycoplasma</em> and other bacterial or viral infections have been associated with a severe reactive mucositis with limited cutaneous involvement that is considered a separate entity. (See  <a class="medical medical_review" href="/z/d/html/120346.html" rel="external">"Reactive infectious mucocutaneous eruption (RIME)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes</strong> – There are rare and controversial reports of SJS/TEN attributed to chemical exposure [<a href="#rid32">32</a>], complementary/traditional medications [<a href="#rid33">33</a>], vaccinations [<a href="#rid34">34-37</a>], and foods [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic SJS/TEN</strong> – In at least 15 percent of cases, no clear exposure to drugs or other triggers can be identified [<a href="#rid22">22</a>]. Whether occult exposures to drugs present in complementary medications, foods, or yet-to-be-identified infectious agents are implicated in idiopathic cases has not been determined [<a href="#rid39">39,40</a>].</p><p></p><p class="headingAnchor" id="H77486418"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>SJS/TEN is predominantly a drug-specific T cell-mediated reaction. The human leukocyte antigen (HLA)-drug-T cell receptor (TCR) engagement results in the activation of drug-specific CD8+ T cells with subsequent release of cytotoxic proteins, resulting in epidermal necrolysis [<a href="#rid41">41-44</a>].</p><p>The main pathogenic sequence can be summarized as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic predisposition (HLA polymorphism and pharmacogenetics)</p><p class="bulletIndent1"><span class="glyph">●</span>Drug antigen presentation</p><p class="bulletIndent1"><span class="glyph">●</span>T cell-mediated response and immune dysregulation</p><p class="bulletIndent1"><span class="glyph">●</span>Release of cytotoxic mediators, death signals, and keratinocyte cell death</p><p></p><p class="headingAnchor" id="H3404085926"><span class="h2">HLA polymorphism and pharmacogenetics</span><span class="headingEndMark"> — </span>A genetic predisposition to SJS/TEN has been established. The association of certain HLA haplotypes with an increased risk of SJS/TEN is restricted to certain ethnicities and specific drugs  (<a class="graphic graphic_table graphicRef142089" href="/z/d/graphic/142089.html" rel="external">table 2</a>). Examples of at-risk HLA phenotypes include HLA B*5801 in Han Chinese, Malay, Thai, European, and Korean populations in relation to allopurinol-induced SJS/TEN [<a href="#rid44">44-46</a>] and HLA B*1502 in Han Chinese, Thai, and Malay populations in relation to carbamazepine-induced SJS/TEN [<a href="#rid44">44,47,48</a>].</p><p>Genome-wide association studies have further identified other genetic variants that may increase the risk of SJS/TEN. These include variants in cytochrome P450 2C9 enzyme, which reduces drug clearance and is associated with phenytoin-related severe cutaneous adverse reactions [<a href="#rid49">49</a>], as well as a slow acetylator genotype that increases the risk for sulfonamide-induced TEN [<a href="#rid50">50,51</a>]. Additionally, adenosine triphosphate (ATP)-binding cassette (ABC) transporters and proteosome complex have been implicated [<a href="#rid52">52</a>].</p><p>Screening for HLA B*1502 is recommended in patients of Asian ancestry prior to initiating treatment with <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid53">53</a>]. Several studies have shown the reduction of SJS/TEN with the use of preinitiation genetic screening in Asian countries such as Taiwan, Singapore, and Thailand [<a href="#rid54">54,55</a>]. (See  <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring", section on 'Role of pretreatment HLA testing'</a>.)</p><p class="headingAnchor" id="H3432141601"><span class="h2">Models of drug-induced T cell activation</span><span class="headingEndMark"> — </span>HLA-drug-TCR synapse is the initial step in the pathogenesis of SJS/TEN. Various models have been proposed to explain how the inciting drug is recognized by TCRs to activate adaptive responses:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hapten/prohapten model</strong> – The drug/metabolite binds covalently to an endogenous protein that undergoes intracellular processing. When these modified peptides are presented with an HLA molecule to the TCRs on T cells, they are recognized as foreign, and an immune response is elicited. The model has been used to explain beta-lactam-induced drug hypersensitivity [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic interaction of drugs with immune receptors model</strong> – The drug/metabolite binds directly and noncovalently to the HLA molecule or TCR. This has been demonstrated for HLA B*1502 and carbamazepine-associated SJS/TEN [<a href="#rid57">57,58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Altered peptide model</strong> – In this model, the binding of the drug to HLA results in a conformational change, thereby altering the HLA binding specificity. This allows for a new repertoire of self-peptides to be bound and presented, resulting in an alloreactive T cell response. This model has been used to demonstrate <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> drug hypersensitivity [<a href="#rid59">59,60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Altered T cell receptor model</strong> – Similar to the altered peptide model, binding of the drug/metabolite to TCR results in a conformational change, altering the specificity of HLA self-peptides [<a href="#rid61">61</a>].</p><p></p><p class="headingAnchor" id="H2078088371"><span class="h2">T cell-mediated response and immune dysregulation</span><span class="headingEndMark"> — </span>The main cellular effectors of SJS/TEN are CD8+ cytoxic T cells, which possess the relevant TCR clonotypes to facilitate the HLA-drug-TCR engagement [<a href="#rid42">42,62,63</a>]. This interaction results in the activation of the cytotoxic CD8+ T cells with the subsequent release of cytotoxic proteins, resulting in epidermal necrolysis. Besides cytotoxic T cells, other involved cellular mediators include natural killer (NK)/T cells, NK cells, and T helper type 17 (Th17) cells as evidenced by their presence in TEN blister fluids [<a href="#rid64">64</a>]. In addition, the impairment of T regulatory cell function during the acute phase may potentiate the immune dysregulation [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H2739745527"><span class="h2">Cytotoxic mediators, death signals, and cell death</span><span class="headingEndMark"> — </span>Fulminant keratinocyte death and full-thickness epidermal detachment marks the final stage of TEN pathogenesis. Various cytotoxic proteins and cytokines, such as soluble granulysin, Fas ligand, perforin/granzyme, tumor necrosis factor (TNF)-alpha, and TNF-related apoptosis-inducing ligand, have been proposed as mediators [<a href="#rid64">64,66-68</a>]. Granulysin, a cytolytic protein found in cytotoxic T cells, NK/T cells, and NK cells, is now recognized as the most important mediator of keratinocyte death in SJS/TEN [<a href="#rid64">64</a>].</p><p>The predominant mechanism of cell death in TEN is thought to be apoptosis [<a href="#rid69">69</a>]. However, studies suggest that necroptosis, a form of programmed cell death with necrosis and inflammation, may play a role as well. Necroptosis may be mediated via annexin A1/RIP3 pathways [<a href="#rid70">70-72</a>].</p><p>Various cytokines/chemokines have also been implicated in SJS/TEN. TNF-alpha is increased [<a href="#rid73">73</a>], and interleukin (IL) 15 is associated with mortality and severity [<a href="#rid74">74</a>]. IL-15 is a widely expressed cytokine produced by many cell types, including immune cells (eg, monocytes, macrophages, and dendritic cells) and keratinocytes. IL-15 has a key role in promoting and maintaining long-lasting cytotoxic T cell and NK cell responses. In in vitro models, the addition of exogenous IL-15 has been shown to increase the secretion of granulysin and, to a lesser extent, of granzyme from blister fluid cells from patients with TEN [<a href="#rid74">74</a>].</p><p>In addition to these mediators, other cytokines such as interferon (IFN)-gamma, IL-2, IL-5, IL-6, IL-10, IL-12, IL-13, IL-18, IL-33, CCR3, CXCR3, CXCR45, and CCR10 may be involved in the trafficking, proliferation, and activation of T cells as well as the amplification of both the innate and acquired immune response [<a href="#rid25">25,75-77</a>].</p><p>Apart from the adaptive immune system, the innate system has been increasingly implicated in the disease mechanism. Neutrophils have been implicated in the activation and amplification of TEN via neutrophil extracellular traps [<a href="#rid78">78</a>]. Induction and increased expressions of alarmins have also been observed in TEN [<a href="#rid77">77,79</a>].</p><p class="headingAnchor" id="H854081208"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H3077539339"><span class="h2">Prodromal symptoms</span><span class="headingEndMark"> — </span>Prodromal symptoms of SJS/TEN include malaise, fever, myalgia, sore throat, and conjunctivitis. These symptoms may precede or occur concurrently with the mucocutaneous presentation [<a href="#rid1">1,80,81</a>].</p><p class="headingAnchor" id="H2350596400"><span class="h2">Cutaneous lesions</span><span class="headingEndMark"> — </span>The initial cutaneous presentation of SJS/TEN may mimic an exanthematous rash. Lesions start on the face and thorax before spreading to other areas and are symmetrically distributed. Early lesions typically begin with ill-defined, coalescing, erythematous macules, which evolve over the course of one to two days to develop dusky erythema, purpuric spots, atypical targets (atypical targets have two rings instead of the three typically seen in target lesions of erythema multiforme), and flaccid bullae  (<a class="graphic graphic_picture graphicRef76141 graphicRef67632 graphicRef66134" href="/z/d/graphic/76141.html" rel="external">picture 1A-C</a>).</p><p>As the disease progresses, extensive, sheet-like detachment and erosions occur  (<a class="graphic graphic_picture graphicRef68458 graphicRef59418" href="/z/d/graphic/68458.html" rel="external">picture 2A-B</a>). Nikolsky sign (the ability to extend the area of epidermal detachment with gentle lateral pressure) is positive. The scalp is typically not affected; painful, edematous erythema typically develops on the palms and soles  (<a class="graphic graphic_picture graphicRef142092" href="/z/d/graphic/142092.html" rel="external">picture 3</a>) [<a href="#rid1">1,80,81</a>].</p><p>Skin tenderness is prominent in SJS/TEN, and the diagnosis must be suspected in anyone who presents with a tender, extensive, mucocutaneous eruption.</p><p>The acute, progressive phase of the disease lasts for approximately seven to nine days from initial symptoms before the process arrest. From disease arrest, the skin re-epithelizes over 7 to 21 days [<a href="#rid3">3,82</a>].</p><p>During the active phase of the disease, the patient is at risk of fluid and electrolyte imbalances, increased metabolic demands, sepsis, hypothermia, organ decompensation, and death due to the extensive skin detachment ("skin failure") [<a href="#rid1">1,81,83</a>].</p><p class="headingAnchor" id="H2856455175"><span class="h2">Extracutaneous involvement and complications</span></p><p class="headingAnchor" id="H1474258974"><span class="h3">Mucosal involvement</span><span class="headingEndMark"> — </span>All mucosal surfaces can be involved during the acute phase of the disease and often include the buccal, oro/nasopharyngeal, and anogenital mucosa. In up to 80 percent of patients, two or more mucosal surfaces are involved [<a href="#rid1">1,80</a>]. Oral cavity involvement is the most common (90 percent of patients), followed by nasal (50 percent), ear (50 percent), and laryngeal involvement (30 percent) [<a href="#rid84">84</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Oral mucosal involvement may take the form of erosions, blisters, and hemorrhagic cheilitis  (<a class="graphic graphic_picture graphicRef68682 graphicRef73805" href="/z/d/graphic/68682.html" rel="external">picture 4A-B</a>). Nasopharyngeal involvement may include erosions, blisters, epistaxis, and epiglottitis. Severe laryngeal involvement may be associated with a higher risk of acute pulmonary involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genital involvement can be seen in up to 60 to 70 percent of patients and commonly presents as erosions and blisters [<a href="#rid85">85,86</a>]. Extensive pain and dysuria may lead to acute urinary retention. In females, vulvovaginal involvement may present with erosive and ulcerative vaginitis, vulvar bullae, vaginal synechiae, and may lead to long-term anatomic sequelae. These include labial and vaginal adhesions and stenosis [<a href="#rid87">87,88</a>].</p><p></p><p class="headingAnchor" id="H3315125127"><span class="h3">Eye involvement</span><span class="headingEndMark"> — </span>Ocular involvement is common (affecting 60 to 100 percent of patients) and may present as conjunctival hyperemia  (<a class="graphic graphic_picture graphicRef93290" href="/z/d/graphic/93290.html" rel="external">picture 5</a>), pseudomembrane formation, or complete corneal epithelial defect [<a href="#rid89">89</a>]. Acute ocular surface involvement can be graded as follows [<a href="#rid90">90</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>No ocular involvement – 0 (none)</p><p class="bulletIndent1"><span class="glyph">●</span>Conjunctival hyperemia – 1 (mild)</p><p class="bulletIndent1"><span class="glyph">●</span>Either ocular surface epithelial defect or pseudomembrane formation – 2 (severe)</p><p class="bulletIndent1"><span class="glyph">●</span>Both ocular surface epithelial defect and pseudomembrane formation – 3 (very severe)</p><p></p><p>Acute ocular involvement is the strongest predictor for long-term ocular complications [<a href="#rid91">91-93</a>]. Between 20 to 75 percent of SJS/TEN survivors have chronic eye sequelae, which include lid ectropion/entropion; trichiasis; distichiasis; symblepharon and forniceal shortening; persistent corneal epithelial defect, thinning, scarring, and keratinization; dry eyes; and reduced visual acuity [<a href="#rid91">91,94,95</a>]. (See  <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae", section on 'Eyes'</a>.)</p><p class="headingAnchor" id="H2281285288"><span class="h3">Renal involvement</span><span class="headingEndMark"> — </span>Acute kidney injury is common and has been reported in approximately 20 to 30 percent of SJS/TEN cases [<a href="#rid96">96,97</a>]. Proteinuria can occur in up to 60 percent of patients [<a href="#rid98">98</a>]. In a French retrospective cohort study that included 245 patients admitted for SJS/TEN, renal replacement therapy was initiated in approximately 10 percent of patients during their hospital stay [<a href="#rid99">99</a>]. Risk factors for renal replacement therapy include the presence and severity of acute renal failure on admission, larger body surface area (BSA) involvement, and score of toxic epidermal necrolysis (SCORTEN) values. Patients requiring renal replacement therapy had a significantly higher in-hospital mortality than those not requiring it (82 versus 9 percent) [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H1962451311"><span class="h3">Pulmonary involvement</span><span class="headingEndMark"> — </span>During the acute phase of the disease, respiratory complications are frequent. These include specific lung injury (eg, sloughing of the bronchial epithelium), as well as nonspecific complications, such as pneumonia, pulmonary edema, and atelectasis. Twenty-five percent of patients with pulmonary involvement may develop acute respiratory failure requiring mechanical ventilation [<a href="#rid100">100</a>].</p><p class="headingAnchor" id="H2580093736"><span class="h3">Gastrointestinal involvement</span><span class="headingEndMark"> — </span>Gastrointestinal involvement in SJS/TEN is not well defined. Clinical presentations may include abdominal pain, diarrhea, hematemesis, melena/rectal bleeding, or ileus. In a retrospective review of 20 patients with SJS/TEN admitted to an intensive care unit who underwent endoscopic procedures, 11 patients (55 percent) had definite SJS/TEN-related lesions (eg, epithelial detachment, mucosal ulceration, stricture) mostly involving the esophagus [<a href="#rid101">101</a>].</p><p class="headingAnchor" id="H1441646687"><span class="h3">Liver injury</span><span class="headingEndMark"> — </span>In a study of 298 cases of SJS/TEN from China, drug-induced liver injury occurred in 40 patients (13 percent) [<a href="#rid102">102</a>]. In another cohort from Australia, drug-induced liver injury occurred in up to 30 percent of patients with SJS/TEN. Independent risk factors for drug-induced liver injury include underlying liver disease, hyperlipidemia, and diabetes [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H1985340085"><span class="h3">Hematologic abnormalities</span><span class="headingEndMark"> — </span>Hematologic abnormalities (eg, anemia, leukopenia, thrombocytopenia) are common in SJS/TEN [<a href="#rid80">80</a>]. In a review of 377 patients with SJS/TEN, 13 percent of patients had leukopenia during the acute phase of the disease [<a href="#rid104">104</a>]. Disseminated intravascular coagulation has been reported in over 20 percent of patients with SJS/TEN [<a href="#rid105">105,106</a>].</p><p class="headingAnchor" id="H304131284"><span class="h3">Bacteremia and sepsis</span><span class="headingEndMark"> — </span>Bacteremia occurs in up to 30 to 50 percent of patients with SJS/TEN and is associated with a three- to fourfold increased mortality risk. Sepsis and septic shock are the main causes of death in these patients, accounting for approximately 50 percent of deaths from SJS/TEN.</p><p>Risk factors for bacteremia include age &gt;40 years, white blood cell &gt;10,000, BSA involvement &gt;10 percent, hemoglobin &lt;10 g/dL, and underlying cardiovascular diseases [<a href="#rid107">107-109</a>]. Bacteremia is most often caused by <em>Staphylococcus aureus</em>, <em>Pseudomonas aeruginosa</em>, and other gram-negative bacteria. In specialized burn units and intensive care units, nosocomial organisms (eg, <em>Acinetobacter baumannii</em>) may also be isolated [<a href="#rid108">108,109</a>].</p><p class="headingAnchor" id="H2528209621"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of SJS/TEN is based on clinical presentation, history, and supportive histologic evidence.</p><p class="headingAnchor" id="H3551094917"><span class="h2">Clinical findings and history</span><span class="headingEndMark"> — </span>The diagnosis of a severe cutaneous adverse reaction should be suspected in any patient presenting with a sudden onset of a painful mucocutaneous eruption associated with systemic symptoms and a history of recent exposure to drugs  (<a class="graphic graphic_table graphicRef91163" href="/z/d/graphic/91163.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1872339764"><span class="h2">Drug causality assessment</span><span class="headingEndMark"> — </span>Drug causality assessment hinges on two factors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Latency</strong> – An exposure to the suspected drug for an extended period of one to four weeks (less commonly eight weeks) prior to the onset of the reaction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug notoriety </strong>– Information about the drugs that are most frequently associated with SJS/TEN, based on epidemiologic studies and pharmacovigilance,<strong> </strong>is helpful for the diagnosis  (<a class="graphic graphic_table graphicRef91163" href="/z/d/graphic/91163.html" rel="external">table 1</a>).</p><p></p><p>The algorithm of drug causality for epidermal necrolysis (ALDEN) has been developed as a tool for the rapid assessment of drug causality  (<a class="graphic graphic_table graphicRef93517" href="/z/d/graphic/93517.html" rel="external">table 3</a>). ALDEN is based on six parameters, including drug notoriety, half-life, latency, rechallenge results, and presence of alternative explanations [<a href="#rid22">22</a>]. The ALDEN score is especially useful for clinicians who may be unfamiliar with the assessment of drug causality in severe cutaneous reactions.</p><p class="headingAnchor" id="H3422732106"><span class="h2">Skin biopsy</span><span class="headingEndMark"> — </span>A skin biopsy for routine histopathologic examination and direct immunofluorescence may be helpful for supporting the diagnosis of SJS/TEN and excluding other disorders that may mimic SJS/TEN. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Classic histopathologic features of SJS/TEN include basal keratinocyte apoptosis in the early stage of the disease, evolving to full-thickness necrolysis and separation of the epidermis at the dermo-epidermal junction as the disease progresses. The dermal inflammatory infiltrate is typically mild and consists primarily of T lymphocytes [<a href="#rid110">110</a>]. Direct immunofluorescence is always negative [<a href="#rid111">111</a>].</p><p class="headingAnchor" id="H2374023784"><span class="h2">Laboratory and imaging studies</span><span class="headingEndMark"> — </span>The laboratory and imaging evaluation of patients with SJS/TEN includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential, coagulation studies, metabolic panel (ie, glucose, electrolytes, blood urea nitrogen, creatinine, calcium, total protein, albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase), erythrocyte sedimentation rate, and C-reactive protein.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial and fungal cultures should be performed from blood, wounds, and mucosal lesions. Because of the high risk of bacterial superinfection and sepsis, cultures should be repeated at frequent intervals during the acute phase of the disease.</p><p></p><p class="bulletIndent1">Procalcitonin may be useful as an early diagnostic marker of bacteremia. The presence of raised procalcitonin and hypothermia has been associated with a higher incidence of blood culture positivity [<a href="#rid107">107</a>]. Skin cultures have good negative predictive values for<em> S. aureus</em> and<em> P. aeruginosa</em> bacteremia if skin swabs are negative for these organisms [<a href="#rid109">109</a>]. (See  <a class="medical medical_review" href="/z/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children, as well as in adults without a clear drug causality, polymerase chain reaction and/or serology for <em>Mycoplasma pneumoniae</em> infection should be obtained in the early stage of disease and three weeks later. (See  <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A chest radiograph should be obtained in all patients due to the possibility of pulmonary involvement of SJS/TEN, pneumonia, and interstitial pneumonitis (see <a class="local">'Pulmonary involvement'</a> above). If indicated, other imaging modalities/procedures, such as computed tomography (CT) scans and bronchoscopy, may be necessary.</p><p></p><p class="headingAnchor" id="H3603353018"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of SJS/TEN includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythema multiforme </strong>– Erythema multiforme (EM) is an immune-mediated disorder most commonly triggered by infections and characterized by an eruption of typical target lesions  (<a class="graphic graphic_picture graphicRef79955 graphicRef62370 graphicRef72055" href="/z/d/graphic/79955.html" rel="external">picture 6A-C</a>), which are circular papules and plaques with three distinct rings (a darker center with or without a blister followed by a pale, pink ring and a bright red, outermost ring). Distribution of EM is typically acral, and the extent of involvement is usually limited. In contrast, target lesions in SJS/TEN are atypical (flat and lacking the three rings) and distributed on the trunk and head/neck. Moreover, dusky erythema, flaccid bulla, and sheet-like skin detachment do not occur in EM. On histology, EM demonstrates an interface dermatitis with a lichenoid infiltrate and epidermal necrosis that is mainly limited to the basal layer, whereas in SJS/TEN, there is extensive epidermal necrosis with minimal inflammatory infiltrate [<a href="#rid111">111</a>]. (See  <a class="medical medical_review" href="/z/d/html/5559.html" rel="external">"Erythema multiforme: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exanthematous drug eruptions</strong> – The generalized and symmetric maculopapular erythema of an exanthematous drug eruption can mimic the initial presentation of SJS/TEN  (<a class="graphic graphic_picture graphicRef86552 graphicRef54205" href="/z/d/graphic/86552.html" rel="external">picture 7A-B</a>). However, exanthematous drug eruptions lack mucosal involvement, the prominent skin pain of TEN, blisters, and epidermal detachment [<a href="#rid112">112</a>]. Histology may show only a mild interface dermatitis with a perivascular, inflammatory infiltrate of lymphocytes, neutrophils, and eosinophils without the full-thickness epidermal necrolysis  (<a class="graphic graphic_picture graphicRef86550" href="/z/d/graphic/86550.html" rel="external">picture 8</a>). (See  <a class="medical medical_review" href="/z/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug reaction with eosinophilia and systemic symptoms </strong>–<strong> </strong>The cutaneous eruption of drug reaction with eosinophilia and systemic symptoms (DRESS) is widespread and may be polymorphous, ranging from an exanthematous eruption to confluent erythema to generalized exfoliative dermatitis. Sheet-like detachment is never present  (<a class="graphic graphic_table graphicRef86557" href="/z/d/graphic/86557.html" rel="external">table 4</a>). Facial edema is prominent. Mucosal involvement is infrequent and typically mild. Ocular involvement is rare. In addition to the cutaneous findings, systemic involvement and lymphadenopathy are frequently present [<a href="#rid113">113</a>]. (See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute generalized exanthematous pustulosis </strong>– Severe cases of acute generalized exanthematous pustulosis (AGEP) may be difficult to differentiate from SJS/TEN  (<a class="graphic graphic_table graphicRef86557" href="/z/d/graphic/86557.html" rel="external">table 4</a>) [<a href="#rid114">114</a>]. AGEP typically develops within a few days of exposure to the offending drug, most often a beta-lactam antibiotic. Clinical features include numerous pinpoint pustulosis on a background of erythema  (<a class="graphic graphic_picture graphicRef56807" href="/z/d/graphic/56807.html" rel="external">picture 9</a>). The condition resolves without treatment in one to two weeks after drug discontinuation. The histologic hallmark of AGEP is a spongiform, subcorneal, and/or intraepidermal pustule  (<a class="graphic graphic_picture graphicRef56807" href="/z/d/graphic/56807.html" rel="external">picture 9</a>). (See  <a class="medical medical_review" href="/z/d/html/15761.html" rel="external">"Acute generalized exanthematous pustulosis (AGEP)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Generalized bullous fixed drug eruption</strong> – Generalized bullous fixed drug eruption is characterized by discrete, well-defined, large, dusky, violaceous patches with or without blisters or erosions. The intervening areas between lesions are typically spared. Although the mucosae can be involved, ocular involvement is never present [<a href="#rid115">115</a>]. (See  <a class="medical medical_review" href="/z/d/html/15760.html" rel="external">"Fixed drug eruption", section on 'Generalized bullous fixed drug eruption'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staphylococcal scalded skin syndrome </strong>–<strong> </strong>Staphylococcal scalded skin syndrome (SSSS) is a disorder primarily affecting young children although it may occur in adults in the setting of immunosuppression, chronic kidney disease, and other severe comorbidities. SSSS is characterized by painful erythema, extensive peeling, and erosions. Mucous membranes are not affected. Histopathology can differentiate SSSS and SJS/TEN. (See  <a class="medical medical_review" href="/z/d/html/114922.html" rel="external">"Staphylococcal scalded skin syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute graft-versus-host disease </strong>–<strong> </strong>Acute graft-versus-host disease (GVHD) is a complication of allogenic hematopoietic stem cell transplant. The most severe form of GVHD (grade 4) has similar clinical findings of widespread erythema, blistering, and oral mucositis, although the clinical course is subacute. (See  <a class="medical medical_review" href="/z/d/html/13760.html" rel="external">"Cutaneous manifestations of graft-versus-host disease (GVHD)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reactive infectious mucocutaneous eruption </strong>– Reactive infectious mucocutaneous eruption (RIME) is a reactive parainfectious mucocutaneous eruption that is commonly attributed to <em>Mycoplasma</em> and other infective agents, such as <em>Chlamydia pneumoniae</em>, human metapneumovirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, parainfluenza, and influenza B virus. Although mucositis is prominent  (<a class="graphic graphic_picture graphicRef126081" href="/z/d/graphic/126081.html" rel="external">picture 10</a>), often affecting two or more mucous membranes, cutaneous involvement is typically limited or absent [<a href="#rid116">116</a>]. (See  <a class="medical medical_review" href="/z/d/html/120346.html" rel="external">"Reactive infectious mucocutaneous eruption (RIME)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SJS/TEN-like acute cutaneous lupus</strong> <strong>erythematosus</strong> – This is a rare manifestation of systemic lupus erythematosus that mimics TEN clinically. Differentiation between the two may be challenging. In SJS/TEN-like acute lupus, the skin lesions may be photodistributed; associated with a recent flare of lupus; and have a longer, protracted clinical course. In addition, although the oral mucosa may be involved in SJS/TEN-like lupus, genital and ocular involvement are uncommon. On histology, the finding of junctional vacuolar alteration associated with a moderate to dense periadnexal and perivascular lymphocytic infiltrate with melanophages and mucin points to a lupus erythematosus-related origin. Direct immunofluorescence is rarely positive in TEN-like lupus erythematosus cases but, if present, suggests an lupus erythematosus diagnosis [<a href="#rid15">15,117</a>]. (See  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Acute cutaneous lupus erythematosus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paraneoplastic pemphigus</strong> – Paraneoplastic pemphigus is a rare disorder that can represent the initial presentation of a malignancy or occur in a patient with a known neoplastic process, such as non-Hodgkin lymphoma in adults or Castleman disease in children. Patients may develop severe mucocutaneous disease with ocular and oral blisters and skin lesions  (<a class="graphic graphic_picture graphicRef67265 graphicRef62146 graphicRef59594" href="/z/d/graphic/67265.html" rel="external">picture 11A-C</a>). (See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Linear IgA bullous dermatosis</strong> – Linear IgA (immunoglobulin A) bullous dermatosis is a rare autoimmune blistering disease that may mimic TEN  (<a class="graphic graphic_picture graphicRef64559" href="/z/d/graphic/64559.html" rel="external">picture 12</a>). Histology reveals a subepidermal blister with an underlying, neutrophil-predominant, dermal infiltrate. Direct immunofluorescence shows linear deposits of IgA along the basement membrane. (See  <a class="medical medical_review" href="/z/d/html/15301.html" rel="external">"Linear IgA bullous dermatosis"</a>.)</p><p></p><p class="headingAnchor" id="H746541189"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109237.html" rel="external">"Society guideline links: Drug allergy and hypersensitivity"</a>.)</p><p class="headingAnchor" id="H4251711"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87114.html" rel="external">"Patient education: Stevens-Johnson syndrome and toxic epidermal necrolysis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H177928752"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, severe mucocutaneous reactions triggered, in most cases, by medications and characterized by extensive necrosis and detachment of the epidermis. SJS and TEN exist as a continuum and are classified based on the percentage of skin body surface area (BSA) detached:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>&lt;10 percent of BSA detached – SJS</p><p class="bulletIndent2"><span class="glyph">•</span>10 to 30 percent of BSA detached – SJS/TEN overlap</p><p class="bulletIndent2"><span class="glyph">•</span>&gt;30 percent of BSA detached – TEN</p><p></p><p class="bulletIndent1">However, we use the term "SJS/TEN" to refer collectively to SJS, TEN, and SJS/TEN overlap syndrome. (See <a class="local">'Introduction and classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology and risk factors</strong> – Medications are the leading trigger of SJS/TEN in both adults and children. <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">Allopurinol</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, aromatic anticonvulsants, antibacterial sulfonamides, and "oxicam" or cyclooxygenase-2 (COX-2) inhibitor nonsteroidal anti-inflammatory drugs (NSAIDs) are most commonly implicated  (<a class="graphic graphic_table graphicRef91163" href="/z/d/graphic/91163.html" rel="external">table 1</a>). Risk factors for SJS/TEN include HIV infection, genetic factors, underlying autoimmune diseases, and malignancy. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – SJS/TEN begins with a prodrome of fever and influenza-like symptoms one to three days before the development of mucocutaneous and skin lesions. The cutaneous eruption typically starts with ill-defined, coalescing, erythematous macules with atypical target lesions  (<a class="graphic graphic_picture graphicRef67632 graphicRef68458 graphicRef59418 graphicRef66134" href="/z/d/graphic/67632.html" rel="external">picture 1B-C, 2A-B</a>). As the disease progresses, vesicles and bullae form, and within days the skin begins to slough. Mucosal involvement occurs in approximately 90 percent of cases of SJS/TEN and can precede or follow the skin eruption. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – In severe cases with extensive skin detachment, acute complications may include massive loss of fluids and electrolyte imbalance, hypovolemic shock with renal failure, bacteremia, insulin resistance, hypercatabolic state, and multiple organ dysfunction syndrome. (See <a class="local">'Extracutaneous involvement and complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of SJS/TEN is based upon clinical and histologic findings in a patient with a history of antecedent drug exposure or febrile illness. Histologic findings on skin biopsy are supportive but not independently diagnostic. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H3407628648"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Milton H Nirken, MD, now deceased, who contributed to an earlier version of this topic review.</p><p>The UpToDate editorial staff also acknowledges Jean-Claude Roujeau, MD, and Whitney A High, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272.</a></li><li><a class="nounderline abstract_t">Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129:92.</a></li><li><a class="nounderline abstract_t">Heng YK, Lee HY, Roujeau JC. Epidermal necrolysis: 60 years of errors and advances. Br J Dermatol 2015; 173:1250.</a></li><li><a class="nounderline abstract_t">Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J Invest Dermatol 2016; 136:1387.</a></li><li><a class="nounderline abstract_t">Chaby G, Maldini C, Haddad C, et al. Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) in France during 2003-16: a four-source capture-recapture estimate. Br J Dermatol 2020; 182:618.</a></li><li><a class="nounderline abstract_t">Frey N, Jossi J, Bodmer M, et al. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J Invest Dermatol 2017; 137:1240.</a></li><li><a class="nounderline abstract_t">Hsu DY, Brieva J, Silverberg NB, et al. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol 2017; 76:811.</a></li><li><a class="nounderline abstract_t">Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128:35.</a></li><li><a class="nounderline abstract_t">Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 2013; 133:1197.</a></li><li><a class="nounderline abstract_t">Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15:1843.</a></li><li><a class="nounderline abstract_t">Saka B, Barro-Traoré F, Atadokpédé FA, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Int J Dermatol 2013; 52:575.</a></li><li><a class="nounderline abstract_t">Yang C, Mosam A, Mankahla A, et al. HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4⁺ T cells. J Am Acad Dermatol 2014; 70:1096.</a></li><li><a class="nounderline abstract_t">Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 2003; 83:1.</a></li><li><a class="nounderline abstract_t">Chimbetete T, Buck C, Choshi P, et al. HIV-Associated Immune Dysregulation in the Skin: A Crucible for Exaggerated Inflammation and Hypersensitivity. J Invest Dermatol 2023; 143:362.</a></li><li><a class="nounderline abstract_t">Ziemer M, Kardaun SH, Liss Y, Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol 2012; 166:575.</a></li><li><a class="nounderline abstract_t">Gillis NK, Hicks JK, Bell GC, et al. Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort. J Invest Dermatol 2017; 137:2021.</a></li><li><a class="nounderline abstract_t">Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58:25.</a></li><li><a class="nounderline abstract_t">Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J 2008; 49:384.</a></li><li><a class="nounderline abstract_t">Ng CY, Yeh YT, Wang CW, et al. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions. J Invest Dermatol 2016; 136:1373.</a></li><li><a class="nounderline abstract_t">Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600.</a></li><li><a class="nounderline abstract_t">Wang YH, Chen CB, Tassaneeyakul W, et al. The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label. Clin Pharmacol Ther 2019; 105:112.</a></li><li><a class="nounderline abstract_t">Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88:60.</a></li><li><a class="nounderline abstract_t">Saw S, Lee HY, Ng QS. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur J Cancer 2017; 81:237.</a></li><li><a class="nounderline abstract_t">Maloney NJ, Ravi V, Cheng K, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol 2020; 59:e183.</a></li><li><a class="nounderline abstract_t">Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004; 123:850.</a></li><li><a class="nounderline abstract_t">Zhu J, Chen G, He Z, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database. EClinicalMedicine 2021; 37:100951.</a></li><li><a class="nounderline abstract_t">Ziemer M, Fries V, Paulmann M, Mockenhaupt M. Epidermal necrolysis in the context of immuno-oncologic medication as well as kinase inhibitors and biologics. J Dtsch Dermatol Ges 2022; 20:777.</a></li><li><a class="nounderline abstract_t">Reschke R, Mockenhaupt M, Simon JC, Ziemer M. Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions. J Dtsch Dermatol Ges 2019; 17:942.</a></li><li><a class="nounderline abstract_t">Kuo AM, Markova A. High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer. Front Med (Lausanne) 2022; 9:898790.</a></li><li><a class="nounderline abstract_t">Ingen-Housz-Oro S, Milpied B, Badrignans M, et al. Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases. Melanoma Res 2022; 32:205.</a></li><li><a class="nounderline abstract_t">Liew YCC, Choo KJL, Oh CC, et al. Mycoplasma-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: Case-control analysis of a cohort managed in a specialized center. J Am Acad Dermatol 2022; 86:811.</a></li><li><a class="nounderline abstract_t">Kamijima M, Hisanaga N, Wang H, Nakajima T. Occupational trichloroethylene exposure as a cause of idiosyncratic generalized skin disorders and accompanying hepatitis similar to drug hypersensitivities. Int Arch Occup Environ Health 2007; 80:357.</a></li><li><a class="nounderline abstract_t">Lim JH, Cho SH, Lee JD, Kim HS. A Case of Stevens-Johnson Syndrome Probably Induced by Herbal Medicine. Ann Dermatol 2018; 30:481.</a></li><li><a class="nounderline abstract_t">Zou H, Daveluy S. Toxic epidermal necrolysis and Stevens-Johnson syndrome after COVID-19 infection and vaccination. Australas J Dermatol 2023; 64:e1.</a></li><li><a class="nounderline abstract_t">Dash S, Sirka CS, Mishra S, Viswan P. COVID-19 vaccine-induced Stevens-Johnson syndrome. Clin Exp Dermatol 2021; 46:1615.</a></li><li><a class="nounderline abstract_t">Calley BJ, Saleh J, Young K, Wanat KA. Stevens-Johnson syndrome in a pregnant woman who received the influenza vaccine. JAAD Case Rep 2022; 23:35.</a></li><li><a class="nounderline abstract_t">Ball R, Ball LK, Wise RP, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J 2001; 20:219.</a></li><li><a class="nounderline abstract_t">Irani C, Haddad F, Maalouly G, Nemnoum R. Curcumin in stevens-johnsons syndrome: culprit or bystander? World Allergy Organ J 2009; 2:59.</a></li><li><a class="nounderline abstract_t">Haddad C, Chosidow O, Valeyrie-Allanore L, et al. Are Idiopathic Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Related to Drugs in Food? The Example of Phenylbutazone. J Invest Dermatol 2017; 137:1179.</a></li><li><a class="nounderline abstract_t">Lim YL, Thirumoorthy T. Serious cutaneous adverse reactions to traditional Chinese medicines. Singapore Med J 2005; 46:714.</a></li><li><a class="nounderline abstract_t">Lee HY, Chung WH. Toxic epidermal necrolysis: the year in review. Curr Opin Allergy Clin Immunol 2013; 13:330.</a></li><li><a class="nounderline abstract_t">Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114:1209.</a></li><li><a class="nounderline abstract_t">Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993; 129:466.</a></li><li><a class="nounderline abstract_t">Gibson A, Deshpande P, Campbell CN, et al. Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. J Allergy Clin Immunol 2023; 151:289.</a></li><li><a class="nounderline abstract_t">Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134.</a></li><li><a class="nounderline abstract_t">Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18:99.</a></li><li><a class="nounderline abstract_t">Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.</a></li><li><a class="nounderline abstract_t">Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, et al. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2013; 149:1025.</a></li><li><a class="nounderline abstract_t">Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 2014; 312:525.</a></li><li><a class="nounderline abstract_t">Wolkenstein P, Carrière V, Charue D, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5:255.</a></li><li><a class="nounderline abstract_t">Shear NH, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105:179.</a></li><li><a class="nounderline abstract_t">Nicoletti P, Bansal M, Lefebvre C, et al. ABC transporters and the proteasome complex are implicated in susceptibility to Stevens-Johnson syndrome and toxic epidermal necrolysis across multiple drugs. PLoS One 2015; 10:e0131038.</a></li><li><a class="nounderline abstract_t">Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9:1543.</a></li><li><a class="nounderline abstract_t">Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011; 364:1126.</a></li><li><a class="nounderline abstract_t">Sung C, Tan L, Limenta M, et al. Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of HLA-B*15:02 Genotyping as Standard-of-Care. Front Pharmacol 2020; 11:527.</a></li><li><a class="nounderline abstract_t">Torres MJ, Mayorga C, García JJ, et al. New aspects in betalactam recognition. Clin Exp Allergy 1998; 28 Suppl 4:25.</a></li><li><a class="nounderline abstract_t">Pichler WJ. The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors. World Allergy Organ J 2008; 1:96.</a></li><li><a class="nounderline abstract_t">Wei CY, Chung WH, Huang HW, et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012; 129:1562.</a></li><li><a class="nounderline abstract_t">Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 2012; 109:9959.</a></li><li><a class="nounderline abstract_t">Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012; 486:554.</a></li><li><a class="nounderline abstract_t">Watkins S, Pichler WJ. Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRVβ20-1, altering pHLA recognition. PLoS One 2013; 8:e76211.</a></li><li><a class="nounderline abstract_t">Ko TM, Chung WH, Wei CY, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011; 128:1266.</a></li><li><a class="nounderline abstract_t">Chung WH, Pan RY, Chu MT, et al. Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions. J Invest Dermatol 2015; 135:2237.</a></li><li><a class="nounderline abstract_t">Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14:1343.</a></li><li><a class="nounderline abstract_t">Takahashi R, Kano Y, Yamazaki Y, et al. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009; 182:8071.</a></li><li><a class="nounderline abstract_t">de Araujo E, Dessirier V, Laprée G, et al. Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol 2011; 20:107.</a></li><li><a class="nounderline abstract_t">Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490.</a></li><li><a class="nounderline abstract_t">Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002; 109:155.</a></li><li><a class="nounderline abstract_t">Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996; 134:710.</a></li><li><a class="nounderline abstract_t">Saito N, Qiao H, Yanagi T, et al. An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions. Sci Transl Med 2014; 6:245ra95.</a></li><li><a class="nounderline abstract_t">Stadler PC, Clanner-Engelshofen BM, Helbig D, et al. Necroptotic and apoptotic cell death in Toxic Epidermal Necrolysis. J Dermatol Sci 2021; 104:138.</a></li><li><a class="nounderline abstract_t">Panayotova-Dimitrova D, Feoktistova M, Leverkus M. RIPping the Skin Apart: Necroptosis Signaling in Toxic Epidermal Necrolysis. J Invest Dermatol 2015; 135:1940.</a></li><li><a class="nounderline abstract_t">Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 1994; 130:605.</a></li><li><a class="nounderline abstract_t">Su SC, Mockenhaupt M, Wolkenstein P, et al. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. J Invest Dermatol 2017; 137:1065.</a></li><li><a class="nounderline abstract_t">Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006; 155:722.</a></li><li><a class="nounderline abstract_t">Correia O, Delgado L, Barbosa IL, et al. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 2002; 47:58.</a></li><li><a class="nounderline abstract_t">Adachi A, Komine M, Tsuda H, et al. Differential expression of alarmins: IL-33 as a candidate marker for early diagnosis of toxic epidermal necrolysis. J Allergy Clin Immunol Pract 2019; 7:325.</a></li><li><a class="nounderline abstract_t">Kinoshita M, Ogawa Y, Hama N, et al. Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis. Sci Transl Med 2021; 13.</a></li><li><a class="nounderline abstract_t">Bellón T, Alvarez L, Mayorga C, et al. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases. Br J Dermatol 2010; 162:1014.</a></li><li><a class="nounderline abstract_t">Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23:1039.</a></li><li><a class="nounderline abstract_t">Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet 2017; 390:1996.</a></li><li><a class="nounderline abstract_t">Lee HY, Dunant A, Sekula P, et al. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol 2012; 167:555.</a></li><li><a class="nounderline abstract_t">Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol 2016; 174:1194.</a></li><li><a class="nounderline abstract_t">Bequignon E, Duong TA, Sbidian E, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission. JAMA Dermatol 2015; 151:302.</a></li><li><a class="nounderline abstract_t">Gulanikar A, Abrol A, Sagar S. Study of genital manifestations of Stevens Johnson Syndrome/Toxic Epidermal Necrolysis. Indian J Sex Transm Dis AIDS 2022; 43:39.</a></li><li><a class="nounderline abstract_t">Meneux E, Wolkenstein P, Haddad B, et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol 1998; 91:283.</a></li><li><a class="nounderline abstract_t">Emberger M, Lanschuetzer CM, Laimer M, et al. Vaginal adenosis induced by Stevens-Johnson syndrome. J Eur Acad Dermatol Venereol 2006; 20:896.</a></li><li><a class="nounderline abstract_t">Noël JC, Buxant F, Fayt I, et al. Vulval adenosis associated with toxic epidermal necrolysis. Br J Dermatol 2005; 153:457.</a></li><li><a class="nounderline abstract_t">Morales ME, Purdue GF, Verity SM, et al. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN. Am J Ophthalmol 2010; 150:505.</a></li><li><a class="nounderline abstract_t">Sotozono C, Ang LP, Koizumi N, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology 2007; 114:1294.</a></li><li><a class="nounderline abstract_t">Gueudry J, Roujeau JC, Binaghi M, et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009; 145:157.</a></li><li><a class="nounderline abstract_t">López-García JS, Rivas Jara L, García-Lozano CI, et al. Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis. Ophthalmology 2011; 118:265.</a></li><li><a class="nounderline abstract_t">Kinoshita F, Yokota I, Mieno H, et al. Multi-state model for predicting ocular progression in acute Stevens-Johnson syndrome/toxic epidermal necrolysis. PLoS One 2021; 16:e0260730.</a></li><li><a class="nounderline abstract_t">Lee HY, Walsh SA, Creamer D. Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. Br J Dermatol 2017; 177:924.</a></li><li><a class="nounderline abstract_t">Sotozono C, Ueta M, Nakatani E, et al. Predictive Factors Associated With Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Am J Ophthalmol 2015; 160:228.</a></li><li><a class="nounderline abstract_t">Hung CC, Liu WC, Kuo MC, et al. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol 2009; 29:633.</a></li><li><a class="nounderline abstract_t">Lee TH, Lee CC, Ng CY, et al. The influence of acute kidney injury on the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis: The prognostic value of KDIGO staging. PLoS One 2018; 13:e0203642.</a></li><li><a class="nounderline abstract_t">Blum L, Chosidow O, Rostoker G, et al. Renal involvement in toxic epidermal necrolysis. J Am Acad Dermatol 1996; 34:1088.</a></li><li><a class="nounderline abstract_t">Papo M, Valeyrie-Allanore L, Razazi K, et al. Renal replacement therapy during Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective observational study of 238 patients. Br J Dermatol 2017; 176:1370.</a></li><li><a class="nounderline abstract_t">de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med 2014; 42:118.</a></li><li><a class="nounderline abstract_t">Gendreau S, Amiot A, Le Baleur Y, et al. Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case series. Br J Dermatol 2019; 180:1234.</a></li><li><a class="nounderline abstract_t">Zhang Z, Li S, Zhang Z, et al. Clinical Features, Risk Factors, and Prognostic Markers of Drug-Induced Liver Injury in Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Indian J Dermatol 2020; 65:274.</a></li><li><a class="nounderline abstract_t">Fang WC, Adler NR, Graudins LV, et al. Drug-induced liver injury is frequently associated with severe cutaneous adverse drug reactions: experience from two Australian tertiary hospitals. Intern Med J 2018; 48:549.</a></li><li><a class="nounderline abstract_t">Wang LL, Noe MH, Micheletti RG. Prevalence of Leukopenia and Associated Outcomes in Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. JAMA Dermatol 2022; 158:1212.</a></li><li><a class="nounderline abstract_t">Chen CB, Hsu TH, Chung-Yee Hui R, et al. Disseminated intravascular coagulation in Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol 2021; 84:1782.</a></li><li><a class="nounderline abstract_t">El-Azhary RA, Nowsheen S, Gibson LE, DiCaudo DJ. Disseminated intravascular coagulopathy: a complication of Stevens-Johnson syndrome/toxic epidermal necrolysis. Int J Dermatol 2021; 60:185.</a></li><li><a class="nounderline abstract_t">Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123:1160.</a></li><li><a class="nounderline abstract_t">Koh HK, Chai ZT, Tay HW, et al. Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients. J Am Acad Dermatol 2019; 81:686.</a></li><li><a class="nounderline abstract_t">de Prost N, Ingen-Housz-Oro S, Duong Ta, et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore) 2010; 89:28.</a></li><li><a class="nounderline abstract_t">Rzany B, Hering O, Mockenhaupt M, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996; 135:6.</a></li><li><a class="nounderline abstract_t">Côté B, Wechsler J, Bastuji-Garin S, et al. Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1995; 131:1268.</a></li><li><a class="nounderline abstract_t">Stern RS. Clinical practice. Exanthematous drug eruptions. N Engl J Med 2012; 366:2492.</a></li><li><a class="nounderline abstract_t">Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169:1071.</a></li><li><a class="nounderline abstract_t">Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol 2001; 28:113.</a></li><li><a class="nounderline abstract_t">Lipowicz S, Sekula P, Ingen-Housz-Oro S, et al. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2013; 168:726.</a></li><li><a class="nounderline abstract_t">Ramien ML, Bruckner AL. Mucocutaneous Eruptions in Acutely Ill Pediatric Patients-Think of Mycoplasma pneumoniae (and Other Infections) First. JAMA Dermatol 2020; 156:124.</a></li><li><a class="nounderline abstract_t">Lee HY, Tey HL, Pang SM, Thirumoorthy T. Systemic lupus erythematosus presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of three cases. Lupus 2011; 20:647.</a></li></ol></div><div id="topicVersionRevision">Topic 2091 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7794310" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Severe adverse cutaneous reactions to drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420497" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26769645" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidermal necrolysis: 60 years of errors and advances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27039263" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31396952" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) in France during 2003-16: a four-source capture-recapture estimate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28202399" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28285784" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17805350" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23389396" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11579247" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23330601" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24629995" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4⁺T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12636014" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Severe cutaneous reactions associated with the use of human immunodeficiency virus medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36549954" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : HIV-Associated Immune Dysregulation in the Skin: A Crucible for Exaggerated Inflammation and Hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22014091" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28549953" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919772" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18465047" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26996548" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7477195" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29569740" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20375998" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28438440" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32052409" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15482470" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evaluation of the potential role of cytokines in toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34386743" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35711043" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Epidermal necrolysis in the context of immuno-oncologic medication as well as kinase inhibitors and biologics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31210413" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35770005" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35377864" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33915240" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mycoplasma-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: Case-control analysis of a cohort managed in a specialized center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17106739" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Occupational trichloroethylene exposure as a cause of idiosyncratic generalized skin disorders and accompanying hepatitis similar to drug hypersensitivities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30065594" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A Case of Stevens-Johnson Syndrome Probably Induced by Herbal Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36484649" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Toxic epidermal necrolysis and Stevens-Johnson syndrome after COVID-19 infection and vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34081806" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : COVID-19 vaccine-induced Stevens-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35391912" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Stevens-Johnson syndrome in a pregnant woman who received the influenza vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11224848" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23282983" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Curcumin in stevens-johnsons syndrome: culprit or bystander?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28108296" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Are Idiopathic Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Related to Drugs in Food? The Example of Phenylbutazone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16308646" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Serious cutaneous adverse reactions to traditional Chinese medicines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23799330" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Toxic epidermal necrolysis: the year in review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15536433" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8466217" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36740326" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15743917" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18192896" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15057820" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Medical genetics: a marker for Stevens-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23884208" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25096692" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8528274" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3729200" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26110827" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : ABC transporters and the proteasome complex are implicated in susceptibility to Stevens-Johnson syndrome and toxic epidermal necrolysis across multiple drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18855540" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21428768" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32457602" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of HLA-B*15:02 Genotyping as Standard-of-Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9761026" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : New aspects in betalactam recognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23282405" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22322005" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22645359" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22722860" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24116097" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRVβ20-1, altering pHLA recognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21924464" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25946710" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029983" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19494333" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21255088" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9774279" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11799383" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8733377" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25031270" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34656387" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Necroptotic and apoptotic cell death in Toxic Epidermal Necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26174536" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : RIPping the Skin Apart: Necroptosis Signaling in Toxic Epidermal Necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8179342" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28011147" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16965421" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12077582" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29936189" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Differential expression of alarmins: IL-33 as a candidate marker for early diagnosis of toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34193610" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20030638" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2273103" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Toxic epidermal necrolysis (Lyell syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28476287" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Severe cutaneous adverse reactions to drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22639874" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27317286" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671761" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35846537" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Study of genital manifestations of Stevens Johnson Syndrome/Toxic Epidermal Necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9469290" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16898932" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Vaginal adenosis induced by Stevens-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16086774" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Vulval adenosis associated with toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20619392" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17475335" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19221260" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20884054" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34941887" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Multi-state model for predicting ocular progression in acute Stevens-Johnson syndrome/toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28144971" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25979679" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Predictive Factors Associated With Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155617" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30192870" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The influence of acute kidney injury on the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis: The prognostic value of KDIGO staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8647982" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Renal involvement in toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27510226" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Renal replacement therapy during Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective observational study of 238 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989174" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30430542" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32831367" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Clinical Features, Risk Factors, and Prognostic Markers of Drug-Induced Liver Injury in Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29316113" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Drug-induced liver injury is frequently associated with severe cutaneous adverse drug reactions: experience from two Australian tertiary hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35976636" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Prevalence of Leukopenia and Associated Outcomes in Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32828861" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Disseminated intravascular coagulation in Stevens-Johnson syndrome and toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332598" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Disseminated intravascular coagulopathy: a complication of Stevens-Johnson syndrome/toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3632000" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31195022" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20075702" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8776350" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503570" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22738099" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Clinical practice. Exanthematous drug eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23855313" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11168761" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23413807" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31851301" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Mucocutaneous Eruptions in Acutely Ill Pediatric Patients-Think of Mycoplasma pneumoniae (and Other Infections) First.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148602" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Systemic lupus erythematosus presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of three cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
